De Ritis described the ratio between the serum levels of aspartate transaminase (AST) and
alanine transaminase (ALT) almost 50 years ago. While initially described as a characteristic …

Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver
diseases. Experimental evidence suggests three major mechanisms of action:(1) protection …

Aims: To assess the place of AST/ALT ratio (the ratio of serum aspartate aminotransferase to
serum alanine aminotransferase) as a diagnostic marker in medical populations. Methods …

2 Московский государственный медико-стоматологический университет им. АИ
Евдокимова, кафедра пропедевтики внутренних болезней и гастроэнтерологии 3 …

Background: Many patients with primary biliary cirrhosis (PBC) are asymptomatic at the time
of diagnosis. However, because most studies of asymptomatic PBC have been small and …

Background & Aims: Ursodeoxycholic acid (UDCA) is used for treatment of primary biliary
cirrhosis. Previous studies showed that, compared with UDCA monotherapy, bile salts plus …

Background Ursodeoxycholic acid (UDCA) is the only approved treatment for primary biliary
cirrhosis, but its effect on disease progression and survival is uncertain. The aim of this study …

Primary biliary cirrhosis (PBC) is an immune-mediated chronic cholestatic liver disease with
a slowly progressive course. Without treatment, most patients eventually develop fibrosis …

Primary biliary cirrhosis (PBC) is an uncommon, chronic, cholestatic liver disease of
unknown etiology characterized by necrosis of intrahepatic bile ducts and progressive portal …

Ursodeoxycholic acid (UDCA) is widely used for the treatment of a variety of chronic
cholestatic liver diseases. At present, it is the only drug approved by the United States Food …